Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 102Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma 29Prostatic Neoplasms 28Leukemia, Monocytic, Acute 26Leukemia, Erythroblastic, Acute 23Congenital Abnormalities 23Leukemia, Myelomonocytic, Acute 22Leukemia, Megakaryoblastic, Acute 21Myelodysplastic Syndromes 17Lymphoma, Non-Hodgkin 17Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 16Recurrence 14Lymphoma, Large-Cell, Immunoblastic 10Leukemia, Lymphocytic, Chronic, B-Cell 10Leukemia, Biphenotypic, Acute 9Lymphoma, Mantle-Cell 8Burkitt Lymphoma 7Breast Neoplasms 7Anemia, Refractory, with Excess of Blasts 6Neoplasms 5Leukemia, Promyelocytic, Acute 5Hodgkin Disease 5Blast Crisis 5Ovarian Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Leukemia, Basophilic, Acute 4

Interventions

venetoclax 1olutasidenib 1magrolimab 1fludarabine 1cc-486 1Mitoxantrone 1Etoposide 1Dexamethasone 1Decitabine 1Cytarabine 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myeloid Malignancies × Mitoxantrone × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡